De Novo & PMA Approvals
Novel device classification, evidence strategy, and benefit-risk justification determine De Novo and PMA success
Key Outcomes
A clear pathway to De Novo classification or PMA approval
Reduced review deficiencies and more predictable timelines
A complete, inspection-ready submission package
A complete evidence justification aligned with FDA expectations
Emerging and high-risk medical technologies require structured pathways for De Novo classification or PMA approval, each demanding a complete evidence architecture, benefit-risk justification, and alignment between device functionality, claims, and regulatory expectations. Unlike 510(k) submissions, these pathways require direct demonstration of safety and effectiveness through comprehensive clinical evidence, extensive bench testing, human factors validation, and full documentation of design controls and risk management. Many MedTech companies encounter delays because their evidence plans, labeling language, or submission structure do not align with FDA review expectations for these more stringent pathways.
UnifiMed provides a complete approval strategy that integrates regulatory, clinical, and risk management frameworks to support a predictable De Novo or PMA review.
CHALLENGES
Typical Deficiencies in De Novo and PMA Submissions
Across innovative and higher-risk technologies, several issues consistently delay De Novo or PMA submissions
Evidence packages that fall short of FDA expectations for demonstrating safety and effectiveness
Clinical studies that lack sufficient endpoints, powering, or protocol discipline to support approval
Risk management files that do not meet the depth, traceability, or documentation rigor required for De Novo or PMA review
Design controls and verification plans that fail to substantiate technological safety or performance claims
Labeling and claims that exceed what the data supports or conflict with risk and testing documentation
Submission narratives that fail to provide a clear benefit-risk rationale supported by available evidence
These gaps lead to deficiencies, extended review cycles, and heightened regulatory uncertainty
OUR PROCESS
How We Build FDA Regulatory Strategy and Pre-Sub Planning
UnifiMed provides an integrated strategy that strengthens early interactions with FDA and supports a predictable regulatory pathway
Pathway Assessment and Approval Strategy
We determine whether De Novo or PMA is the correct pathway by assessing device risk, intended use, regulatory classifications, and available evidence. Our team evaluates eligibility for De Novo classification or confirms PMA requirements, maps FDA safety and effectiveness expectations, and aligns labeling boundaries to pathway-specific criteria. This establishes the regulatory foundation and defines the evidence required for approval
Predicate, Reference Device, and Technological Comparison Logic
We assess reference devices and technological comparators to support risk categorization for De Novo; for PMA, we document technological differences and safety rationale. We analyze intended use alignment, design characteristics, and risk controls to define how your device fits within or departs from existing regulatory structures. This ensures FDA receives a clear justification for classification and review approach
Clinical and Non-Clinical Evidence Strategy
We build the evidence architecture required to demonstrate safety and effectiveness, including pivotal clinical design, endpoint selection, performance testing, biocompatibility, electrical safety, software documentation, and statistical requirements. Our team aligns all testing and clinical activities with FDA standards and benefit-risk expectations. This produces a coherent evidence plan that supports a defensible approval package
Risk Management, Design Controls, and Technical Docs
We structure the risk file, verification and validation documentation, and design history components to meet De Novo and PMA expectations. This includes ISO 14971 alignment, mapping of risk controls to testing data, and ensuring design controls fully support safety and performance claims. This creates a technically sound foundation that withstands FDA scrutiny
Human Factors, Usability, and Labeling Integration
We align human factors validation, usability evidence, and labeling content with the device’s intended use, risk profile, and operational environment. Our team refines claims, instructions for use, and user interface documentation to ensure consistency with clinical and non-clinical evidence. This prevents review deficiencies and supports safe, effective use
Submission Assembly and FDA Review Support
We prepare the complete De Novo or PMA submission, organizing modules, integrating clinical and technical evidence, and constructing a clear benefit-risk narrative. Our team manages FDA communication planning, meeting preparation, and responses to review questions, including advisory committee readiness when applicable. This ensures a structured, defensible submission and a more predictable review process
Ready to Learn More?
Contact our team to discuss how we can support your De Novo or PMA approvals